Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the New Drug Application (NDA) for its
investigational fertility treatment, corifollitropin alfa, has been
accepted for standard review by the U.S. Food and Drug Administration
(FDA). Merck is seeking FDA approval of corifollitropin alfa for
Controlled Ovarian Stimulation (COS) in women participating in assisted
reproductive technology.
Language:
English
Contact:
MerckMedia:Pam Eisele, 908-423-5042orTina Grasso, 267-893-9783orInvestors:Carol Ferguson, 908-423-4465
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more